Trisura Group Q2 Earnings: Strong Underwriting, Discounted Valuation, and the Market's Remaining Doubt

Trisura Group hit a milestone most Canadian specialty insurers never reach: total book value past CAD 1 billion, more than a year ahead of its 2027 target. The second-quarter report, released August 6, came with an 84.9% combined ratio, 10% operating EPS growth, and 18% growth in investment income.

But the stock sits near CAD 42 — about 2 times book value and, by some analyst accounts, 36% below the consensus fair-value estimate. The underwriting numbers say one thing. The price says another. The gap between them is the real story.

What the underwriting stack tells you

The consolidated combined ratio (the ratio of losses and expenses to earned premiums — anything below 100% means the company earns money from writing insurance itself) came in at 84.9%, improved 0.7 points from last year's quarter. The loss ratio dropped to 32.8% from 33.2%. The expense ratio ticked down to 52.1% from 52.4%.

For context, the specialty P&C peer group has a 10-year average combined ratio closer to 90%. Trisura's 10-year average sits at 84%. This is not a one-quarter anomaly — it is a sustained structural advantage.

The segment-level breakdown reinforces the point. Surety underwriting income rose 44% on a 17% loss ratio. Corporate insurance underwriting income was up 60%, with the U.S. team posting its largest-ever single month in June. Warranty premium grew 19%, though management expects a slightly higher combined ratio for the remainder of 2026 due to business mix and elevated claims on select programs — a temporary headwind rather than a structural shift.

Where the earnings came from

Operating EPS of CAD 0.76, up 10.1% year over year. Net EPS of CAD 0.89, up 17.1%. Book value per share jumped 20.2% to CAD 21.19.

Two-thirds of the earnings growth came from the underwriting side (net insurance revenue up 1.4%), one-third from investment income (up 18.1% to CAD 22.3 million). Higher rates have been a tailwind for the entire P&C sector, but Trisura's investment book is positioned to capture more of it: the debt-to-capital ratio sits at 16.5%, still well below the long-term target of 25%, meaning there is room to add duration and leverage without stressing the balance sheet.

Operating ROE of 16.7% is below last year's quarter (18.6%), but management attributes the decline to pre-funding the U.S. Surety balance sheet — a deliberate choice to sacrifice near-term capital efficiency for future scale. The mid-teens ROE target the company has defended for years is intact.

The U.S. expansion is the growth engine and the execution risk

About 45% of 2026 Surety premiums are expected to come from the U.S., up from a fraction of total premiums two years ago. The platform now operates in 48 states, including California (which won't materially impact premiums until next year due to rate-filing timing). The U.S. Surety balance sheet was capitalized with an additional CAD 50 million this quarter, bringing it to CAD 150 million.

Management's stated ambition is for U.S. platforms to eventually equal or exceed the earnings contribution of the Canadian business. That's an aggressive trajectory. It's also the main thing investors are pricing cautiously.

The Canadian fronting business, meanwhile, is softening. Management expects 2026 premiums to decline as the market becomes more competitive. The segment still contributes roughly CAD 5 million in quarterly underwriting income, so the absolute risk is bounded — but it removes a source of margin that was previously growing.

Why the valuation discount persists

At roughly 2x book value, Trisura trades materially below specialty P&C peers, whose median is closer to 2.9x. A comparable name like Kinsale Group trades near 7x book. Even broadly, Canadian insurance peers — Intact Financial at 15.4x earnings, Great-West Lifeco at 18.6x — command higher multiples than Trisura's estimated low-teens P/E.

Three factors explain the discount.

First, the fronting business structure. Trisura's U.S. Programs segment retains only 5–15% of the risk it writes, passing the remainder to reinsurers like Swiss Re. That creates counterparty concentration risk: if a major reinsurer defaults, the impact could be severe. It's a structural feature of the model, not a new risk, but it keeps the stock from trading at the same multiple as a pure carrier.

Second, the gap between operating and actual ROE. Historically, reported operating ROE has exceeded actual ROE by roughly 8 percentage points due to write-downs on exited lines. Management has said it wants these to converge, but as long as they don't, the discount has a factual basis.

Third, insider selling. CEO David Clare and several other executives have sold notable amounts of stock since 2022. Not every sale signals a problem, but it removes one of the usual conviction signals that would otherwise narrow the valuation gap.

What would change the equation

The factor stack — strong underwriting discipline, above-peer combined ratios, mid-teens ROE, and a balance sheet with room for more deployment — points to a company that should trade closer to its specialty peers. The question is whether the catalyst for a re-rating arrives from execution (U.S. Surety scaling to plan, Canadian fronting holding steady) or from a broader market realization that the discount no longer reflects the actual risk.

Watch three things: the convergence of operating versus actual ROE, the trajectory of U.S. premium growth against the 45% Surety target, and whether Canadian fronting declines more than management expects. Any deterioration in the combined ratio would widen the discount further. Any sustained quarter where operating and actual ROE align while the U.S. platform delivers, and the market has a harder case for the current gap.

A stock with a 16.7% operating ROE and a sub-85% combined ratio trading at half the book-value multiple of its best peer is not a mystery. It's a gap. The job is to decide whether the gap reflects genuine risk or market impatience.